HOME Study: Hysteroscopic Office Myomectomy Evaluation (HOME)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01152112
Recruitment Status : Completed
First Posted : June 29, 2010
Results First Posted : September 13, 2017
Last Update Posted : September 13, 2017
Information provided by (Responsible Party):
Hologic, Inc.

Brief Summary:
The purpose of this study is to demonstrate safety and effectiveness of the MyoSure Tissue Removal System when used by community gynecologists in an office setting for the treatment of patients with symptomatic intrauterine polyps and submucosal fibroids.

Condition or disease Intervention/treatment Phase
Uterine Fibroids Polyps Device: Myomectomy Not Applicable

Detailed Description:
Approximately one hundred subjects will be enrolled in a randomized, comparative setting study conducted at 10-15 investigational sites. Sixty subjects will be randomized to undergo treatment in an office setting, and 40 subjects will be randomized to undergo treatment in a hospital or ambulatory surgical center (ASC) setting. Subjects will undergo a hysteroscopic tissue removal procedure to remove intrauterine polyps, type 0 fibroids, or type I fibroids. Saline infused sonohysterogram images (SIS) obtained at three months post treatment will be compared to pre-treatment images, to determine the percent reduction in target pathology volume. Additionally, subject self-reported pain scores (as rated on an 11 point scale) will compare pain occurring during the treatment procedure to the average pain level experienced during a PAP smear. Economic data will be collected and compared between the two treatment settings.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 74 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Hysteroscopic Office Myomectomy Evaluation Using the MyoSure Tissue Removal System for the Removal of Uterine Fibroids and Polyps in the Treatment of Abnormal Uterine Bleeding (AUB)
Study Start Date : June 2010
Actual Primary Completion Date : January 2012
Actual Study Completion Date : June 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Uterine Fibroids
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Treatment, Office Setting, myomectomy
Myomectomy for uterine polyps and/or fibroids occurring in an office setting
Device: Myomectomy
Removal of fibroids and / or polyps
Other Names:
  • Fibroid removal
  • Polyp removal
Experimental: Treatment, Hospital Setting, myomectomy
Myomectomy for uterine polyps and/or fibroids occurring in a hospital setting
Device: Myomectomy
Removal of fibroids and / or polyps
Other Names:
  • Fibroid removal
  • Polyp removal

Primary Outcome Measures :
  1. Percent Reduction in Target Pathology Volume [ Time Frame: Three months post treatment ]
    Percent reduction in target pathology volume, compared between pre-treatment baseline and 3 months post MyoSure treatment

Secondary Outcome Measures :
  1. Percent of Subjects That Achieve 100% Removal of Target Pathology [ Time Frame: Three months post treatment ]
    Percent volume reduction of target pathology between baseline and month three post treatment assessments, as measured by saline infused sonohysterogram.

  2. Subject Self-reported Pain Score Occurring During the Treatment Procedure [ Time Frame: 1 hour post treatment ]
    Mean difference in pain score compared between subject-rated assessment of pain occurring during a pap smear and pain occurring during the MyoSure treatment procedure, based on the Wong-Baker Faces Rating Scale (FRS)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Healthy female between 18 and 55 years of age
  • Subject must be able to understand, read and sign the study specific informed consent forms after the nature of the study has been fully explained to her
  • Subject is a pre-menopausal or peri-menopausal female, either nulliparous or parous
  • Subject is experiencing AUB as confirmed by a symptom raw score of 23 or a calculated symptom score of 44.0 or higher on the Uterine Fibroid Scale and Health Related Quality of Life (UFS-QOL)
  • Subject is indicated for myomectomy or polypectomy for benign appearing pathology, based on a hysteroscopic exam and measured by saline infused sonogram assessment within 30 days of the planned index procedure
  • Subject exhibits intrauterine polyps and/or submucous myomas which, in the opinion of the treating physician, are compatible with office-based treatment (e.g. 15 minutes or less of cutting time) using the MyoSure device and meet at least one of the following criteria:
  • One or more polyps, with at least one of the polyps ≥ 1.5 cm and ≤ 3.0 cm diameter and having broad based attachment to the uterine wall.
  • Up to two Type 0 or Type 1 myomas with at least one of the myomas being ≥ 1.5 cm and none of the myomas being 3.0 cm diameter

    • If the first myoma is 3.0 cm, the second myoma must be ≤ 2.0 cm
    • Fundal myomas must be Type 0
  • Polyps plus up to two Type 0 or Type I myomas with at least one of the myomas being ≥ 1.5cm and ≤ 3.0 cm
  • The subject demonstrates a negative pregnancy test within 48 hours prior to the planned index procedure
  • The subject must document a score of 5 or lower on the Pap Smear and Blood Draw scales of the Pain Tolerance Survey

Exclusion Criteria:

  • Subject has known or suspected cancer, including breast, endometrial, and ovarian
  • Contraindication and/or allergy to local anesthetic, or oral medications specified in the treatment protocol
  • The subject has a history of chronic narcotic use
  • Previous uterine artery embolization or other uterine artery occlusion procedure (Doppler or laparoscopic)
  • Subject has blood borne pathogens-HIV, hepatitis B, CJD, etc.
  • Subject has an IUD at the time of the procedure. A subject may be enrolled in the study if the IUD is removed prior to the treatment procedure
  • Subject is taking an anticoagulant or antiplatelet medication other than low dose aspirin
  • Active pelvic inflammatory disease or pelvic/vaginal infection
  • Subject has a known or suspected coagulopathy or bleeding disorder
  • Subject has a history of unmanaged endocrine disease
  • Subject has current or past, acute or chronic psychiatric disorder which, in the opinion of the Investigator, may preclude proper evaluation and follow-up
  • Subject has a history of auto-immune, inflammatory, or connective tissue disease
  • Subject has a history of disease which increases the risk for fluid overload (i.e. significant cardiac, hepatic, or renal dysfunction)
  • Uncontrolled hypertension lasting two years or more
  • Use of any experimental drug or device within 30 days prior to the screening visit
  • The subject has a terminal illness that may prevent the completion of any follow-up assessments
  • Any employee or relative of an employee of the Sponsor company or any Investigator site employee or relative of employees working on the study
  • Subject has other co-morbid condition(s) that, in the opinion of the Investigator, could limit the subject's ability to participate in the study or impact the scientific integrity of the study
  • Subject has one of the following:

    • Type II submucosal myoma
    • Type O or Type I submucosal myoma > 3.0 cm
    • Fundal Type I myoma
    • Highly vascularized myoma as determined by SIS or hysteroscopic examination

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01152112

United States, Arizona
Phoenix Gynecology Consultants
Phoenix, Arizona, United States, 85013
United States, Colorado
Boulder Women's Clinic
Boulder, Colorado, United States, 80303
United States, Illinois
Women's Health Care Practice
Champaign, Illinois, United States, 61820
United States, Michigan
The Research Division for Integrated Health Services
Ann Arbor, Michigan, United States, 48106
United States, New Jersey
Rubino OB/Gyn
West Orange, New Jersey, United States, 07052
United States, North Carolina
Williams, Benavides, Marston, & Kaminski
Raleigh, North Carolina, United States, 27609
United States, Ohio
Complete Healthcare for Women
Columbus, Ohio, United States, 43231
United States, South Carolina
Kulbresh Women's Center
Irmo, South Carolina, United States, 29063
Obstetrics and Gynecology
North Charleston, South Carolina, United States, 29406
Sponsors and Collaborators
Hologic, Inc.
Study Director: Edward Evantash, MD Sponsor GmbH

Responsible Party: Hologic, Inc. Identifier: NCT01152112     History of Changes
Other Study ID Numbers: TMP 2009003
First Posted: June 29, 2010    Key Record Dates
Results First Posted: September 13, 2017
Last Update Posted: September 13, 2017
Last Verified: August 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: The Journal of Minimally Invasive Gynecology

Keywords provided by Hologic, Inc.:
uterine fibroids
uterine polyps
local anesthetic
cervical block
pain management

Additional relevant MeSH terms:
Pathological Conditions, Anatomical
Neoplasms, Muscle Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms, Connective Tissue
Connective Tissue Diseases